Prevalence Of Antihypertensive Use Research Articles

Prevalence of Antihypertensive Use in CKD

Prevalence of Antihypertensive Use in CKD

A cohort study of antihypertensive use during pregnancy in South Korea, 2013-2017.

Hypertensive disorder is a common medical condition in pregnancy. However, the recommendations for antihypertensive use during pregnancy are based on limited evidence and various factors affect their selection in clinical practice. We aim to assess the prevalence of antihypertensive use and describe which medications are being used in pregnancy. We conducted a cohort study of all pregnancies resulted in a live birth between 2013 and 2017, by using the Health Insurance Review and Assessment (HIRA) database of South Korea. Based on duration of drug supplied, we examined antihypertensive use during the pre-pregnancy, pregnancy, and postpartum periods. We described the patterns of discontinuing, continuing, switching, and initiating antihypertensive medications during pregnancy. We included 2,030,821 pregnancies, of whom 0.9%, 3.1%, and 1.8% were dispensed antihypertensives in the pre-pregnancy, pregnancy, and postpartum periods, respectively. The most frequent medications used were dihydropyridines (40.7%), beta-blockers (38.4%) and Angiotensin II Receptor Blockers (16.8%) in the first trimester, and dihydropyridines (89.7%) and vasodilators (11.5%) in the third trimester. Among women exposed to antihypertensives during pregnancy, this was the first use in 86.3% of women. Among women receiving antihypertensives before pregnancy, 77.9% discontinued treatment during pregnancy, whereas 13.2% continued to take their pre-pregnancy medications. The prevalence of antihypertensive use during pregnancy was 3.1% in South Korea. Overall, while dihydropyridines were predominant, other types of antihypertensives were also commonly dispensed during pregnancy. It suggests a need to investigate the effect of exposure to various types of antihypertensives of which safety remains unclear during pregnancy.

Gender differences in hypertension awareness, antihypertensive use and blood pressure control in Nepalese adults: findings from a nationwide cross-sectional survey.

The objective of this cross-sectional study was to determine the gender differences in hypertension awareness, antihypertensive use and blood pressure (BP) control among the adult Nepalese population (≥18 years) using data from the nationally representative Nepal Demographic and Health Survey 2016. A weighted sample of 13,393 adults (5620 males and 7773 females) was included in the final analysis. After conducting descriptive analyses with the selective explanatory variable, multivariable logistic regression analysis was performed to assess the association between the outcome variable and the explanatory variables. The strength of the association was expressed in adjusted odds with 95% confidence intervals. A higher proportion of women had their BP checked (87.7% females vs 73.0% males, p<0.001) and were aware of their raised BP (43.9% females vs 37.1% males, p<0.001) compared with men. Although female hypertensive individuals had a higher prevalence of antihypertensive medication use than their male counterparts (50.1% females vs 47.5% males), a higher proportion of male hypertensive participants had their BP controlled (49.2% females vs 53.5% males). Women with the poorest wealth index had a lower prevalence of antihypertensive use than their male counterparts. The odds of having their own BP measured increased with age among men but decreased with age among women. The household wealth index was positively associated with the odds of BP measurement, awareness of own BP and antihypertensive use. This study revealed that although women had a higher prevalence of hypertension awareness and antihypertensive medication use, the practice did not translate into better BP control. Inequality in antihypertensive medication use was observed among the poorest wealth quintiles. Public health programmes in Nepal should focus on reducing these inequalities. Further research is needed to learn why females have poorer control of BP, despite having higher antihypertensive medication use.

Patterns of Antihypertensive Drug Utilization among US Adults with Diabetes and Comorbid Hypertension: The National Health and Nutrition Examination Survey 1999-2014.

Background:Diabetes and hypertension are the 2 leading risk factors for suboptimal cardiovascular and renal outcomes. These 2 conditions often coexist and can benefit from antihypertensive therapy, which may lead to blood pressure control and reduced risk for nephropathy (as evidenced by albuminuria).Objective:To quantify the trends of antihypertensive drug use and to assess the impact of antihypertensive treatment on the prevalence of blood pressure control and albuminuria, among US adults with coexisting diabetes and hypertension.Methods:In this serial cross-sectional study, we analyzed data from the 1999-2014 National Health and Nutrition Examination Survey (N = 3586). We determine the prevalence of antihypertensive use, drug classes used, and their association with blood pressure control and albuminuria.Results:During the study period, the study population experienced substantial increase in antihypertensive treatment (from 84.6% in 1999-2002 to 90.1% in 2011-2014, Ptrend < .01) and blood pressure control (from 37.1% to 46.9%, Ptrend < .01) and decrease in albuminuria (from 39.1% to 31.3%, Ptrend = .02). These trends were particularly pronounced in the subgroups using angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers. In multivariate analysis, Blacks, Hispanics, and males were found more likely to have albuminuria than their respective counterparts. Achieving blood pressure control (odds ratio = 0.40, 95% confidence interval [CI]: 0.32-0.49) was associated with lower rates of albuminuria.Conclusion And Relevance:Despite continued improvement in antihypertensive therapy, the burden of uncontrolled blood pressure and albuminuria remains substantial among US adults with diabetes and hypertension. Tailoring pharmacotherapy based on patient characteristics and comorbidities is needed to further improve these outcomes.

Effect of different methods of accounting for antihypertensive treatment when assessing the relationship between diabetes or obesity and systolic blood pressure

BackgroundUnderlying blood pressure is that observed in the absence of antihypertensive treatment or, among those treated, the estimate of that which would be observed without treatment. This study aims to examine the relationships between diabetes or obesity and underlying systolic blood pressure adjusted for antihypertensive treatment by several methods. MethodsData from two population studies were analyzed—an American Indian community in Arizona and the National Health and Nutrition Examination Surveys. Antihypertensive treatment was accounted for using: no adjustment; antihypertensive use as a covariate; blood pressure dichotomized into normotension and hypertension; addition of a fixed treatment effect; non-parametric algorithm; and censored normal regression. ResultsThe magnitude of association at each time point differed by adjustment method particularly where there was a difference in prevalence of antihypertensive use between people with and without diabetes or obesity. The common methods of ignoring antihypertensive treatment or including it as a covariate in a regression model underestimated the effects of diabetes and obesity on underlying blood pressure, compared to the recommended method of the censored normal regression. ConclusionProper accounting for antihypertensive treatment is needed in interpreting variables that affect blood pressure.

Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population.

Hypertensive disorders occur in approximately 6% to 8% of all pregnancies and are a significant source of maternal and fetal morbidity. Little is known about the range of agents routinely used in practice. We used Medicaid claims from 2000 to 2007 to identify completed pregnancies. We included women who were Medicaid beneficiaries from at least 3 months prior to last menstrual period to 1 month postdelivery, and were successfully linked to infant records. Maternal exposure to antihypertensive medications was derived from Medicaid pharmacy claim files, and duration of exposure was assigned based on the days' supply dispensed. We identified 1,106,757 Medicaid patients in our cohort, of whom 48,453 (4.4%) were exposed to antihypertensive medications during pregnancy. The prevalence of antihypertensive use increased from 3.5% to 4.9% during the study period. Antihypertensive medication users were older than nonusers, more likely to be white or black, and more likely to have comorbid diabetes mellitus and renal disease. Overall, 1.9% of pregnant women were exposed during the first trimester, 1.7% during the second trimester, and 3.2% during the third trimester. The range of antihypertensive medications to which patients were exposed was highly heterogeneous and frequently included agents other than methyldopa or labetalol. Angiotensin-converting enzyme inhibitor exposure, which is contraindicated in late pregnancy, occurred in 928 (4.9%) antihypertensive medication users in the second trimester and 383 (1.1%) in the third trimester. Antihypertensive use during pregnancy is relatively common and increasing. The wide range of agents used during pregnancy includes medications considered contraindicated during pregnancy.

Regarding REGARDS: Does Inflammation Explain Racial and Regional Differences in Cardiovascular Disease Risk?

Although black men and women residing in the US experience the highest rates of mortality from both stroke and coronary heart disease (CHD)1 (1), underlying reasons for these statistics remain uncertain. Although differential traditional risk factors, access to care, and sociodemographic and psychosocial variability between race/ethnic groups might undoubtedly account for some of the observed differences, other factors might be at play. For example, whereas both ischemic stroke and CHD often share atherosclerosis as a core pathogenic element, evidence suggests that in general blacks tend to have less atherosclerotic burden measured by coronary calcium score or angiography than whites (2). Additionally, autopsy results from blacks and whites who succumb to sudden cardiac death indicate that blacks have a higher preponderance of stable plaque than whites (3). Thus, from a pathological perspective, race/ethnic differences in cardiovascular risk require further elucidation. The REGARDS (Reasons for Geographic and Racial Differences in Stroke) study was instituted to examine causes for the excess stroke mortality among US blacks and people living in the stroke belt (4). Previous publications from the study examined individual traditional risk factors for stroke and CHD. Differences between blacks and whites and by region were demonstrated—including differences in the prevalence of blood pressure and antihypertensive use, diabetes, smoking, and left ventricular hypertrophy. The estimated predicted probability of stroke, reflecting a combination of risk factors, showed clear differences by race and sex: blacks had higher 10-year stroke risk than whites (11.3% vs 9.7%, P < 0.0001), largely driven by differences in diabetes and possibly hypertension in the 2 groups (4). The same studies, however, have not explained the differences in stroke by region. Whereas the prevalence of antihypertensive use was higher among both blacks and whites residing in the stroke belt (4), there was a trend toward better treatment and …

Left ventricular long axis dysfunction in adults with “corrected” aortic coarctation is related to an older age at intervention and increased aortic stiffness

Objectives:This study examined the prevalence of left ventricular (LV) long axis dysfunction (LAD, septal annulus pulsed-wave (PW) tissue Doppler imaging (TDI) early diastolic velocity ⩽8 cm/s) in patients with “corrected”...

A Multicenter, Case-Control Study of the Effects of Antihypertensive Therapy on Orthostatic Hypotension, Postprandial Hypotension, and Falls in Octo- and Nonagenarians in Residential Care Facilities

Background: Orthostatic hypotension, postprandial hypotension, and falls are considered to be adverse drug reactions of antihypertensive therapy in older people with comorbidities. Concerns regarding these adverse events may limit the use of antihypertensive agents in this group of people. Objective: The aim of this study was to determine the relationship between antihypertensive therapy in octo- and nonagenarians and the risk for orthostatic hypotension, postprandial hypotension, and falls. Methods: This was a case-control study of octo- and nonagenarians living in residential care facilities who were receiving antihypertensive therapy and a control group who were not receiving antihypertensive therapy. Results: A total of 119 patients, 77 who were receiving regular antihypertensive therapy and 42 who were not taking any antihypertensive agents, were enrolled in the study. The prevalence of antihypertensive use, orthostatic hypotension, postprandial hypotension, and falls was high (65%, 29%, 57%, and 45%, respectively). There were no associations between antihypertensive therapy and orthostatic hypotension, postprandial hypotension, and falls. When individual classes of antihypertensive agents were examined, the only observed association was a negative association (ie, a protective effect) between potassium-sparing diuretics and falls (odds ratio, 0.2; 95% CI, 0.04–1.0). Conclusion: Antihypertensive therapy was not associated with an increased risk for orthostatic hypotension, postprandial hypotension, or falls in this case-control study of octo- and nonagenarians living in residential care facilities.